NeoGenomics, Inc. (NASDAQ:NEO) Receives $11.86 Consensus Price Target from Brokerages

NeoGenomics, Inc. (NASDAQ:NEO) has been given an average recommendation of “Hold” by the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $11.8571.

NEO has been the subject of a number of analyst reports. Needham & Company LLC boosted their target price on shares of NeoGenomics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. UBS Group reissued a “hold” rating on shares of NeoGenomics in a research note on Wednesday, February 18th. William Blair reissued a “market perform” rating on shares of NeoGenomics in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeoGenomics in a research note on Friday, March 27th. Finally, Benchmark reissued a “hold” rating on shares of NeoGenomics in a research note on Wednesday, February 18th.

NeoGenomics Stock Performance

NeoGenomics stock opened at $8.16 on Tuesday. NeoGenomics has a 12-month low of $4.72 and a 12-month high of $13.74. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -9.71 and a beta of 1.72. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.26 and a quick ratio of 3.94. The firm’s fifty day moving average price is $8.99 and its 200 day moving average price is $10.45.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Tuesday, February 17th. The medical research company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The company had revenue of $190.17 million during the quarter, compared to the consensus estimate of $188.25 million. During the same quarter in the previous year, the firm earned $0.04 EPS. The company’s revenue was up 10.6% on a year-over-year basis. On average, research analysts forecast that NeoGenomics will post -0.2 EPS for the current fiscal year.

Insider Transactions at NeoGenomics

In other NeoGenomics news, COO Warren Stone sold 22,128 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total transaction of $276,600.00. Following the completion of the transaction, the chief operating officer directly owned 121,631 shares of the company’s stock, valued at $1,520,387.50. The trade was a 15.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in shares of NeoGenomics by 51.2% in the 1st quarter. Royal Bank of Canada now owns 56,026 shares of the medical research company’s stock worth $532,000 after acquiring an additional 18,966 shares during the period. AQR Capital Management LLC acquired a new stake in shares of NeoGenomics in the 1st quarter worth approximately $271,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of NeoGenomics by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 75,798 shares of the medical research company’s stock worth $719,000 after acquiring an additional 3,254 shares during the period. Intech Investment Management LLC lifted its stake in shares of NeoGenomics by 19.7% in the 1st quarter. Intech Investment Management LLC now owns 151,806 shares of the medical research company’s stock worth $1,441,000 after acquiring an additional 24,965 shares during the period. Finally, Creative Planning lifted its stake in shares of NeoGenomics by 20.4% in the 2nd quarter. Creative Planning now owns 16,735 shares of the medical research company’s stock worth $122,000 after acquiring an additional 2,840 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.